Compare INVE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | ACRV |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 74.0M |
| IPO Year | 1997 | 2022 |
| Metric | INVE | ACRV |
|---|---|---|
| Price | $2.89 | $2.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.50 | ★ $11.67 |
| AVG Volume (30 Days) | 266.3K | ★ 396.8K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.42 | $1.27 |
| 52 Week High | $5.30 | $3.56 |
| Indicator | INVE | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 67.08 |
| Support Level | $2.46 | $2.14 |
| Resistance Level | $3.07 | $2.48 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 89.09 | 77.16 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.